Table 6.

Analyses of diastolic blood pressure.

Trials		MD [95% CI]	P Value
TGY plus ACEI versus ACEI
modified TGY plus captopril versus captopril	1	−6.10 [−9.06, −3.14]	<0.0001
TGY plus captopril versus captopril	1	−5.00 [−5.89, −4.11]	<0.00001
TGY plus captopril versus captopril	1	−3.69 [−4.44, −2.94]	<0.00001
TGY plus captopril versus captopril	1	−3.30 [−7.12, 0.52]	0.09
TGY plus captopril versus captopril	1	−6.28 [−7.55, −5.01]	<0.00001
Meta-Analysis	5	−4.60 [−5.11, −4.09]	<0.00001
TGY plus CCB versus CCB
modified TGY plus nifedipine sustained release tablets versus nifedipine sustained release tablets	1	−10.00 [−12.53, −7.47]	<0.00001
modified TGY plus amlodipine besylate versus amlodipine besylate	1	−8.20 [−8.58, −7.82]	<0.00001
TGY plus nifedipine sustained release tablets versus nifedipine sustained release tablets	1	−7.34 [−7.73, −6.95]	<0.00001
Meta-Analysis	3	−7.98 [−8.85, −7.12]	<0.00001
TGY plus diuretics versus diuretics
modified TGY plus hydrochlorothiazide versus hydrochlorothiazide	1	0.44 [−0.52, 1.40]	0.37
Meta-Analysis	1	0.44 [−0.52, 1.40]	0.37
TGY plus ARB versus ARB
TGY plus telmisartan versus telmisartan	1	−0.80 [−1.57, −0.03]	0.04
Meta-Analysis	1	−0.80 [−1.57, −0.03]	0.04
TGY plus “CCB + ACEI” versus “CCB + ACEI”
modified TGY plus amlodipine besylate and lisinopril versus amlodipine besylate and lisinopril	1	−6.87 [−7.60, −6.14]	<0.00001
Meta-Analysis	1	−6.87 [−7.60, −6.14]	<0.00001